MPA is the most common type of ANCA-associated small vessel vasculitis. It is more prevalent in men, with an average age of onset between the fourth and sixth decades of life.

The FDA has approved avacopan as an adjunctive treatment for adults with severe active ANCA-associated vasculitis, alongside standard therapy, according to a press release. Source: Adobe Stock.

Between the two studies, 477 patients with a diagnosis of ANCA-associated vasculitis were enrolled. All participants also met the criteria for primary systemic vasculitis set by the European ...

The first cases of ANCA-positive vasculitis associated with PTU were described by Dolman and colleagues in 1993. [1] Since then there have been over 40 cases reported in the literature. Presenting ...

The clinical spectrum of antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV) with renal involvement includes forms with a slowly progressive course. These forms are poorly ...

“ANCA-associated vasculitis is officially designated an intractable disease in Japan, indicating a rare disease without any effective treatment but for which long-term treatment is required. There is ...

BioWorld Content on 'ANCA-associated vasculitis'Less than two weeks after Japan’s MHLW became the first regulatory agency to clear avacopan for anti-neutrophil cytoplasmic autoantibody ...

The Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) drugs in development market research report provides comprehensive information on the therapeutics under development ...